BEGIN ARTICLE PREVIEW:
The prodigal spinout returns? Since launching Grail into the world in 2016, Illumina has watched the blood test developer grow into a multibillion-dollar startup enterprise by amassing multiple nine-digit funding rounds. However, Grail’s spending has not been wasteful: It’s also collected clinical data from tens of thousands of patients in a massive bid to prove its liquid biopsy test can detect cancer early.
But now, a week after it has filed to go public—and with commercial launches on the horizon next year—the DNA sequencing giant apparently has decided it’s time for Grail to come home.
Join the world’s top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed
Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.
According to a report from Bloomberg, Illumina has begun talks to acquire the company and could end up paying more than $8 billion, or a third more than its current $6 billion valuation.
Though a final decision has not yet been made, an announcement could come as soon as this week, amounting …
END ARTICLE PREVIEW